Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 2/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.35 |
| ▸ | COMT | P21964 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3664098 | 0.88 | ADRA1A (0.54) | ADRA1ARAB9ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL4029675 | 0.87 | ADRA1A (0.41) | ADRA1ARAB9ANPC1MAPTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4090130 | 0.86 | ADRA1A (0.52) | ADRA1ARAB9ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL4026557 | 0.86 | USP5 (0.40) | HDAC2ADRA1AHDAC1SMN1; SMN2L3MBTL1 | |
| SCHEMBL4028305 | 0.85 | SCD5 (0.45) | HDAC2ADRA1ANPC1HCAR2 | |
| SCHEMBL4026155 | 0.84 | NPC1 (0.41) | ADRA1ARAB9ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL3665381 | 0.84 | ADRA1A (0.44) | ADRA1ARAB9ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL3665069 | 0.83 | HTR7 (0.39) | HDAC2ADRA1AHDAC1SMN1; SMN2L3MBTL1 | |
| SCHEMBL4027548 | 0.83 | HCAR2 (0.47) | HDAC2HDAC1SMN1; SMN2GAAKMT2A | |
| SCHEMBL3665949 | 0.83 | ADRA1A (0.43) | ADRA1ARAB9ANPC1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111542523-B | Heterocyclic compounds as PRMT5 inhibitors | 朱比连特埃皮斯科瑞有限责任公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-111542523-A | Heterocyclic compounds as PRMT5 inhibitors | 朱比连特埃皮斯科瑞有限责任公司 | 2020-08-14 | — | — | CN | disclosed |
| US-8288424-B2 | Substituted tetrahydroimidazopyridine compounds and the use thereof in the treatment of pain and other conditions | GRUENENTHAL GMBH (DE) | 2012-10-16 | — | — | US | disclosed |
| EP-2235013-B1 | SUBSTITUTED TETRAHYDROIMIDAZOPYRIDINE COMPOUNDS AND THE USE THEREOF IN PHARMACEUTICALS | GRUENENTHAL GMBH (DE) | 2012-08-01 | — | — | EP | disclosed |
| EP-2235013-A1 | SUBSTITUTED TETRAHYDROIMIDAZOPYRIDINE COMPOUNDS AND THE USE THEREOF IN PHARMACEUTICALS | Grünenthal GmbH (DE) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009092565-A1 | SUBSTITUTED TETRAHYDROIMIDAZOPYRIDINE COMPOUNDS AND THE USE THEREOF IN PHARMACEUTICALS | Grünenthal GmbH (DE) | 2009-07-30 | — | — | WO | disclosed |
| EP-2083009-A1 | Substituted tetrahydroimidazopyridine compounds and their use in medicine | Grünenthal GmbH (DE) | 2009-07-29 | — | — | EP | disclosed |
| US-20090186902-A1 | Substituted Tetrahydroimidazopyridine Compounds and the Use Thereof in the Treatment of Pain and Other Conditions | GRUENENTHAL GMBH (DE) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186902-A1 | Substituted Tetrahydroimidazopyridine Compounds and the Use Thereof in the Treatment of Pain and Other Conditions | HRH4, TRPV1, QDPR | HDAC2 670/4885ADRA1A 517/4885RAB9A 1304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.